Abstract

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses nivolumab (Opdivo), 360 mg intravenously, every 3 weeks for up to 3 cycles.
 Indication: In combination with platinum-doublet chemotherapy for the neoadjuvant treatment of adult patients with resectable non–small cell lung cancer (tumours ≥ 4 cm or node-positive).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
